Clinical Trial: Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Phase II, Multicenter Study of Decitabine (5-aza-2'Deoxycytidine) in Chronic Myelogenous Leukemia Blast Phase Refractory to Imatinib Mesylate (STI 571)

Brief Summary: To determine the safety and efficacy of decitabine in patients with Philadelphia chromosome-positive chronic myelogenous leukemia blastic phase that were previously treated with imatinib mesylate (STI 571) and became resistant/refractory or were found to be intolerant to the drug.

Detailed Summary:
Sponsor: Astex Pharmaceuticals

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Astex Pharmaceuticals

Dates:
Date Received: July 19, 2002
Date Started: July 2002
Date Completion:
Last Updated: January 22, 2013
Last Verified: June 2008